Literature DB >> 20575001

Enantiomeric 3-chloromandelic acid system: binary melting point phase diagram, ternary solubility phase diagrams and polymorphism.

Tam Le Minh1, Jan von Langermann, Heike Lorenz, Andreas Seidel-Morgenstern.   

Abstract

A systematic study of binary melting point and ternary solubility phase diagrams of the enantiomeric 3-chloromandelic acid (3-ClMA) system was performed under consideration of polymorphism. The melting point phase diagram was measured by means of thermal analysis, that is, using heat-flux differential scanning calorimetry (DSC). The results reveal that 3-ClMA belongs to the racemic compound-forming systems. Polymorphism was found for both the enantiomer and the racemate as confirmed by X-ray powder diffraction analysis. The ternary solubility phase diagram of 3-ClMA in water was determined between 5 and 50 degrees C by the classical isothermal technique. The solubilities of the pure enantiomers are extremely temperature-dependent. The solid-liquid equilibria of racemic 3-ClMA are not trivial due to the existence of polymorphism. The eutectic composition in the chiral system changes as a function of temperature. Further, solubility data in the alternative solvent toluene are also presented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20575001     DOI: 10.1002/jps.22234

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Thermal, Spectroscopic, and Crystallographic Analysis of Mannose-Derived Linear Polyols.

Authors:  Ida Mattsson; Manu Lahtinen; Anssi Peuronen; Abhijit Sau; Andreas Gunell; Tiina Saloranta-Simell; Reko Leino
Journal:  Cryst Growth Des       Date:  2018-04-09       Impact factor: 4.076

2.  Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.

Authors:  Justyna Knapik-Kowalczuk; Daniel Kramarczyk; Karolina Jurkiewicz; Krzysztof Chmiel; Marian Paluch
Journal:  Mol Pharm       Date:  2021-08-22       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.